JonesResearch analyst Justin Walsh downgraded Vor Bio (VOR) to Hold from Buy without a price target after the company announced it is exploring a range of strategic alternatives. The firm cites the wind down of Vor’s clinical and manufacturing operations and its 95% workforce reduction for the downgrade. The company’s planned and ongoing clinical trials as well as manufacturing operations have been suspended immediately, JonesResearch points out.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: